Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps

Future strategies: Sequencing versus combinations in targeted and immune therapy

Date

18 Oct 2020

Session

Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps

Topics

Cytotoxic Therapy;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Paolo Ascierto

Authors

P.A. Ascierto

Author affiliations

  • Melanoma, Cancer Immunotherapy & Developmental Therapeutics, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, 80131 - Napoli/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Management and learnings from toxicity?

Presenter: Caroline Robert

Session: Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps

Resources:

Slides

Webcast

Q&A and live discussion

Presenter: Olivier Michielin

Session: Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.